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Abstract Various novel drugs have recently been evaluated
in clinical trials showing promising effects in patients with
inflammatory bowel disease (IBD). Here, we summarize the
recent literature in the area of emerging therapies in the field of
IBD, with specific focus on anti-integrin antibodies, such as
vedolizumab (anti-α4β7) and etrolizumab (anti-rhuMAbβ7),
and the Janus kinase (JAK) inhibitor tofacitinib.Moreover, we
will discuss efficacy and safety data of golimumab (a new
subcutaneous anti-tumor necrosis factor (TNF) antibody),
Avaxia (an orally delivered anti-TNF antibody), and
Budesonide MMX; all have been developed for the treatment
of ulcerative colitis. Other therapeuticals that might find their
way to the market the coming years include the anti-mucosal
vascular addressin cell adhesion molecule (MAdCAM) PF-
00547659, small molecules (including laquinimod and the
CCR9 antagonist Vercirnon), as well as an orally active
SMAD7 antisense oligonucleotide that showed clinical bene-
fit in Crohn’s disease patients.
Keywords Crohn’s disease (CD) . Inflammatory bowel
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Introduction
Inflammatory bowel diseases (IBD) are chronic inflammatory
disorders of the gastrointestinal tract that comprise Crohn’s
disease (CD) and ulcerative colitis (UC). Advances in under-
standing the pathogenesis of these conditions have led to the
development of new therapies. The most important progress
in the management of IBD patients during the last 15 years has
been the introduction of anti-tumor necrosis factor (TNF)
agents [1–4, 5••]. However, failure to TNF blockers is fre-
quently observed, a problem that complicates clinical manage-
ment. Up to 30 % of IBD patients do not respond to induction
therapy with anti-TNF agents (primary non-response) [6, 7],
and a significant proportion loses response over time
(secondary non-response) [8]. As a consequence, approxi-
mately one third of patients are in clinical remission 1 year
after initiation with anti-TNF agents. Loss of response to
infliximab and adalimumab was calculated to be 13 and
25 % per year, respectively [9, 10]. Recent work showed that
fecal loss of infliximab is associated with primary non-
response in IBD patients (Brandse J et al., abstract presenta-
tion DDW 2013, Gastroenterology, Volume 144, Issue 5,
S-36; Table 1). Higher infliximab doses are likely needed as
induction therapy in case of severe colitis to compensate for
fecal loss of infliximab.
Anti-TNF agents are generally well tolerated, but their use
is linked to safety issues, including risk for infections and
malignancies [11–13]. Hence, there remains an unmet need
for new treatment options for these patients. Several novel
drugs showed potent clinical effects in IBD trials. They in-
clude small molecules interfering with intracellular signaling
pathways and therapeutic antibodies that are directed against
extracellular targets, such as pro-inflammatory cytokines or
receptors. An orally administered antisense nucleotide against
SMAD7 (GED-301) was also used successfully for active CD.
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This review article aims to review efficacy and safety data
from clinical trials with integrin blockers, small molecules,
oral nucleotide therapy against SMAD7, new anti-TNF com-
pounds, and a novel corticosteroid (Budesonide MMX:
Cortiment® and Uceris®). We will also focus on the potential
positioning of the approved agents in the therapeutic arma-
mentarium of IBD.
Novel Anti-TNFAgents: Golimumab and Avaxia
Golimumab (Simponi®), a human monoclonal antibody
against TNF, was recently approved by the US Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) for UC patients with moderate to severe active disease
[14]. Regulatory approval was based on the results of the
Program of Ulcerative Colitis Research Studies Utilizing an
Investigational Treatment (PURSUIT) induction and main-
tenance trial [5••, 15••]. Induction treatment with
golimumab consists of 200 and 100 mg subcutaneously
injected at weeks 0 and 2. Maintenance treatment is given
at doses of 100 mg every 4 weeks in the USA and 50 mg
every 4 weeks in European jurisdictions, except for patients
with a body weight of more than 80 kg where 100 mg is
recommended.
Induction treatment with golimumab in patients with mod-
erate to severe active UC failing standard treatment but naïve
to biologic treatment resulted in significantly greater clinical
response, clinical remission, and mucosal healing rates at
week 6 compared to placebo [5••]. Clinical response rates at
week 6 (primary endpoint of the induction trial) were 51.0,
54.9, and 30.3 % of patients receiving golimumab 200/
100 mg, 400/200 mg, or placebo (p<0.0001 for both
golimumab groups versus placebo), respectively. Clinical re-
mission rates were seen in 17.8, 17.9, and 6.4 % of patients
receiving golimumab 200/100 mg, 400/200 mg, or placebo
(p<0.0001 for both comparisons versus placebo). Mucosal
healing, defined as a Mayo endoscopic score of ≤1 at week
6, was seen in 45.1, 42.3, and 28.7 % of patients receiving
400/200 mg golimumab, 200/100 mg golimumab, or placebo,
respectively (p<0.05 for both comparisons versus placebo).
Patients who responded to golimumab induction therapy were
enrolled in the PURSUIT maintenance trial and were random-
ized to receive 50 or 100 mg golimumab every 4 weeks or
placebo [15••]. Patients who did not respond to golimumab
induction treatment received open-label treatment with
100 mg golimumab every 4 weeks. A novel clinical endpoint,
“continued clinical response” (CCR) defined as clinical re-
sponse at all study visits, was used in this trial for the first
time. CCR up to 54 weeks was seen in 47.0 and 49.7 % of
patients receiving 50 or 100 mg golimumab every 4 weeks,
respectively, compared to 31.2 % in the placebo group (p=
0.010 and p<0.001, respectively). At week 30 and week 54, a
higher percentage of patients in the 100 mg golimumab group
were in clinical remission and had mucosal healing (27.8 and
42.4 %, p=0.004) versus placebo (15.6 and 26.6 %, p=0.002)
or 50 mg golimumab (23.2 and 41.7 %, respectively).
Golimumab induction and maintenance treatment was well
tolerated without new safety signals for this anti-TNF agent
and with surprisingly few local injection reactions and immu-
nogenicity. The decision which anti-TNF agent is recom-
mended for the individual UC patient needs further study,
but it appears that the subcutaneous agents are less potent than
intravenous infliximab, which should be the preferred treat-
ment modality for severe and certainly hospitalized patients.
Avaxia Biologics (Lexington, MA, USA) developed an
orally administered anti-TNF antibody (AVX-470), isolated
from colostrum of dairy cows that had been immunized with
TNF, and tested the drug in patients with acute moderate to
severe UC (Harris M et al., abstract presentation UEGW
2014). Safety (primary endpoint) as well as pharmacokinetics,
immunogenicity, and efficacy (e.g., clinical and endoscopic
response and remission) were evaluated in 36 patients. Sub-
jects received active drug (0.2, 1.6, or 3.5 g/day) or placebo for
four consecutive weeks. The drug was well tolerated. Twenty-
eight percent of the patients receiving active treatment with
AVX-470 showed a clinical response versus 14.3 % in the
placebo group. Dose-related improvements in clinical and en-
doscopic remission were seen at higher doses. Future studies
will have to assess the effects of higher doses and longer
duration of treatment.
Budesonide MMX (Uceris® and Cortiment®)
The use of systemic corticosteroids is associated with many
adverse effects. Budesonide is a corticosteroid with reduced
systemic activity due to limited resorption and high first-pass
metabolism. Budesonide MMX (available as Cortiment® by
Ferring in Europe and Uceris® by Santarus Inc. in the USA) is
a novel once-daily oral formulation that uses colonic-release
multi-matrix system (MMX) technology allowing controlled
release of the drug into the colon [16, 17]. A placebo-
controlled study compared the efficacy and safety of
Budesonide MMX in patients with mild to moderate active
Table 1 Oral presentations
Brandse J et al. Oral presentation DDW 2013
Harris M et al. Oral presentation UEGW 2014
Sands B et al. Poster presentation UEGW 2014
Hanauer S et al. Poster presentation UEGW 2014
Feagan B et al. Poster presentation UEGW 2014
Feagan B et al. Oral presentation CCFA 2013
Monteleone G et al. Oral presentation UEGW 2014
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UC [17]. Patients were randomized to receive Budesonide
MMX (9 or 6 mg/day), Entocort 9 mg/day (e.g., budesonide
controlled ileal-release capsules; AstraZeneca, Södertälje,
Sweden), or placebo once daily for 8 weeks. Combined clin-
ical and endoscopic remission rates (primary endpoint) with
Budesonide MMX 9 mg, Budesonide MMX 6 mg, Entocort,
and placebo were 17.4, 8.3, 12.6, and 4.5 %, respectively (p=
0.0047 for Budesonide MMX 9 mg versus placebo).
A second trial compared Budesonide MMX with
mesalamine and placebo for induction of remission in patients
with mild to moderate active UC [18]. Patients were randomly
assigned to receive Budesonide MMX (9 or 6 mg/day),
mesalamine (2.4 g/day), or placebo for 8 weeks. Clinical re-
mission rates at week 8 (primary endpoint) were 17.9, 13.2,
and 12.1 % in the 9-mg Budesonide MMX, 6-mg Budesonide
MMX, or mesalamine group, respectively, compared with
7.4 % in the placebo group (p=0.0143, p=0.1393, and p=
0.2200 for the three comparisons versus placebo). No signif-
icant differences in adverse events were seen between
Budesonide MMX- and placebo-treated patients in these two
trials (CORE I and II), but the follow-up period was only
8 weeks. Hence, induction treatment with Budesonide MMX
(9 mg once daily) is significantly more effective in achieving
clinical and endoscopic remission versus placebo in patients
with mild to moderately active UC. The agent is currently
approved both in Europe (as Cortiment) and in the USA (as
Uceris®).
At this moment, Budesonide MMX should be considered
as second-line treatment in patients with mild to moderate UC
who fail optimal mesalamine therapy and before the use of
systemic corticosteroids. Since no studies have evaluated ef-
ficacy beyond a treatment period of 8 weeks, Budesonide
MMX is not recommended as maintenance treatment. Since
only one dose is available (9mg/day), a tapering regimen does
not appear to be necessary following successful induction.
Agents Interfering With Leukocyte Trafficking
The pathogenesis of IBD is characterized by leukocyte infil-
tration into the gut which is mediated by chemokines and the
interaction between integrins (located on the cell surface of
lymphocytes) and their specific ligands on gut endothelial
cells. Drugs that selectively target cell adhesion molecules
interfere with T cell trafficking. Natalizumab (Tysabri® or
Antegren®) was the first therapeutic antibody that was tested
in humanswithmultiple sclerosis [19] and CD [20] and blocks
the α4 integrin on lymphocytes constituting immune surveil-
lance in the central nervous system and the gut. Natalizumab
induced and maintained remission in patients with moderate
to severe CD, but was found to carry an increased risk of
progressive multifocal leukoencephalopathy (PML), a central
nervous system JC virus infection that can be lethal due to
impaired central nervous system immune surveillance. Pres-
ence of anti-JC virus antibodies, use of immunosuppressive
agents, and increased duration of natalizumab treatment are
associated with PML risk [21]. The incidence of this infection
is estimated at about 1/300. Shortly after its approval by the
FDA, natalizumab was temporarily withdrawn from the mar-
ket but was then reintroduced in 2006 in the USA using a
surveillance program and only in patients without other im-
munomodulator therapy. The next-generation anti-adhesion
molecules, including vedolizumab, etrolizumab, and PF-
00547659, are more gut selective and have therefore not led
to PML, so far.
Vedolizumab
Vedolizumab (Entyvio®) is the first gut-selective humanized
monoclonal antibody. This drug was approved in 2014 by the
FDA and EMA for both UC and CD, refractory to standard
therapy and/or anti-TNF agents. In contrast to natalizumab,
which lacks selectivity for the gut, vedolizumab specifically
targets α4β7 integrins that is exclusively present on gut-
homing T cells thereby blocking the interaction between
α4β7 and anti-mucosal vascular addressin cell adhesion mol-
ecule (MAdCAM)-1.
GEMINI I was a double-blind phase 3 trial in patients with
moderate to severe UC [22••]. Patients were randomized to
receive vedolizumab (300 mg intravenously) or placebo on
day 1 and day 15. Clinical response at week 6, the primary
endpoint of the induction trial, was achieved in 47 % of pa-
tients receiving vedolizumab compared to 26 % on placebo
(p<0.0001), and clinical remission at week 6 was seen in 17%
on vedolizumab versus 5 % on placebo (p=0.0009). Mucosal
healing rates were 41 and 25 % of patients treated with
vedolizumab versus placebo (p=0.0012). Patients who
achieved a clinical response after induction therapy were ran-
domized to receive placebo or further intravenous
vedolizumab at 300 mg at 4- or 8-week dosing intervals up
to 46weeks. Significantly greater clinical remission rates were
seen in patients receiving vedolizumab versus placebo at week
52 (42 and 45 % in the vedolizumab 8- and 4-weekly groups,
respectively, versus 16 % in the placebo arm; p<0.0001 for
both comparisons versus placebo). Moreover, mucosal
healing rates were significantly higher in the vedolizumab
group compared to placebo (52 and 56 % in the vedolizumab
8- and 4-weekly groups, respectively, versus 20 % in the pla-
cebo group; p<0.0001). Of note, the overall clinical efficacy
was higher with vedolizumab in anti-TNF-naïve patients than
in subjects with prior failure or intolerance to anti-TNF agents.
Clinical remission rates at week 52 were 45 versus 18 % and
37 versus 5 % in UC patients who were naïve and exposed to
prior anti-TNF treatment, respectively.
Clinical response at week 6 was also the primary endpoint
of the induction trial with vedolizumab in patients with
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moderate to severe CD (GEMINI II) [23••]. Clinical remission
at week 6 was seen in 13.3 versus 9.7 % of anti-TNF failures
on vedolizumab and placebo, respectively (p=0.157). Corre-
sponding remission rates were 22.7 versus 10.6 % of patients
who were naïve for anti-TNF agents receiving treatment with
vedolizumab or placebo (p=0.005). At week 10, clinical re-
mission rates were 21.7 versus 11 % in anti-TNF failures on
vedolizumab or placebo (p=0.0008), respectively, and 24.7
versus 15.4 % in anti-TNF-naïve patients receiving
vedolizumab or placebo (p=0.044). Week 52 clinical remis-
sion rates were 52 and 27 % in vedolizumab and placebo-
treated patients who were naïve for anti-TNF agents. In con-
trast, the clinical response rate at week 52 was lower after anti-
TNF failure: 28 versus 13 % in the vedolizumab and placebo
groups, respectively (35 % of vedolizumab-treated CD pa-
tients had received ≥2 anti-TNF agents) [23••]. Recent work
suggested that certain patients benefited from an increase in
vedolizumab dosing frequency from every 8 weeks to every
4 weeks in GEMINI I (UC) or GEMINI II (CD) during the
open-label long-term extension study (GEMINI LTS) (poster
presentation UEGW2014, P1054. Sands B et al.). Overall, the
results with vedolizumab seem to be somewhat better in UC
compared to CD. Most likely, the 6-week time point in CD
was set too early to appreciate optimal efficacy given the
mode of action of this agent. It is recommended that CD pa-
tients that do not show response at week 10 be given an addi-
tional 300-mg infusion at week 10. In the absence of effect at
week 14, it appears logical to discontinue treatment at that
point and consider alternative options.
A placebo-controlled phase 3 trial evaluated efficacy and
safety of vedolizumab in CD patients who had failed anti-TNF
therapy (GEMINI III). In the anti-TNF failure population,
15.2 and 12.1 % of patients receiving vedolizumab or placebo
were in clinical remission at week 6, respectively (p=0.433).
However, vedolizumab was statistically superior to placebo
for inducing clinical remission at week 10 (secondary out-
come parameter). Clinical remission at week 10 was seen in
26.6 % of patients in the vedolizumab group versus 12.1 % in
the placebo arm (p=0.001) [24••].
The 2-year efficacy data of vedolizumab in CD (poster
presentation UEGW 2014, P1059, Hanauer S et al.) and in
UC (poster presentation UEGW 2014, P1667, Feagan B
et al.) were recently presented. Patients with UC (GEMINI
I) and CD (GEMINI II) who completed 52 weeks of
vedolizumab treatment were enrolled in GEMINI LTS show-
ing long-term efficacy and safety for an additional 52 weeks.
Hence, the safety profile of vedolizumab in the GEMINI pro-
gram is reassuring. To date, there have been no cases of PML,
and the incidence of systemic and gastrointestinal infections
was similar among patients on vedolizumab or placebo. Re-
cently, a study has been conducted in order to determine
whether vedolizumab alters T cell subpopulations in cerebro-
spinal fluid. Samples of cerebrospinal fluid were obtained
from healthy volunteers and analyzed by flow cytometry be-
fore and after treatment with vedolizumab. No significant
changes in T cell populations were observed [25].
Among pooled UC and CD patients fromGEMINI I and II,
only 4 % tested positive for anti-vedolizumab antibodies dur-
ing maintenance treatment with vedolizumab. Similar rates of
anti-drug antibodies were observed in the vedolizumabmono-
therapy (only 3 % of patients) and vedolizumab-
immunomodulator combination (4 % had increased anti-
vedolizumab antibody titers) groups. The presence of anti-
vedolizumab antibodies might have clinical implications, but
further studies are needed to look into this question. An im-
portant question to be answered is how vedolizumab should
be positioned in future treatment algorithms. Given its higher
efficacy in TNF-naïve patients and the favorable safety pro-
file, the drug has the potential to become the first line biologic
in UC.
Etrolizumab
The humanized monoclonal antibody etrolizumab
(rhuMAb β7) interferes with leucocyte migration by se-
lectively targeting the β7 subunit of α4β7 and αEβ7
integrins. In a placebo-controlled randomized phase 2
trial, patients with moderate to severe UC received sub-
cutaneous etrolizumab (100 mg at weeks 0, 4, and 8,
with placebo at week 2 or 420 mg at week 0 and
300 mg etrolizumab at weeks 2, 4, and 8) or placebo
[26•]. A significant greater number of patients treated
with the study drug achieved clinical remission at week
10 (primary endpoint) compared to placebo. The prima-
ry endpoint was met by 21 and 10 % of patients in the
100- or 300-mg-etrolizumab group, respectively, and in
0 % of patients receiving placebo. This low placebo
response rate was probably a consequence of careful
patient selection (patients were included with a Mayo
endoscopic subscore ≥2 using central endoscopic read-
ing) and stringent endpoints. Biopsy analysis in this trial
revealed that αE expression could be a suitable bio-
marker to identify patients that are most likely to ben-
efit from etrolizumab treatment [26•]. It was shown that
increased αE expression levels in the inflamed colon
were associated with enhanced clinical benefit of
etrolizumab treatment in UC. High αE expression levels
in baseline biopsies, analyzed with qPCR and immuno-
histochemistry, were enriched for etrolizumab remission
at 10 weeks, with a higher enrichment in anti-TNF-na-
ïve patients. Future trials should further characterize the
potential role of αE as a biomarker and should focus on
long-term follow-up. Larger phase 3 studies have now
been initiated including a head-to-head comparison ver-
sus adalimumab in UC and additional trials in CD.
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PF-00547659
A randomized placebo-controlled trial investigated safety and
efficacy of PF-00547659, a monoclonal antibody against
MAdCAM-1, in patients with active UC [27•]. In total, 80
patients were enrolled receiving a single or three doses of
PF-00547659 (0.03–10 mg/kg, intravenously or subcutane-
ously administered) or placebo at 4-week dosing intervals.
Adverse events were reported in similar proportions of pa-
tients on PF-00547659 versus placebo, the most common ad-
verse event being abdominal pain. PF-00547659 produced
some potential benefits compared to placebo on clinical and
endoscopic efficacy endpoints, but no statistical differences
were found between actively treated patients and placebo.
Clinical response at week 4 was seen in 32 and 52 % of
patients on placebo or PF-0054659 (all doses) (p=0.102).
Week 12 clinical response rates were 21 versus 42 % in the
placebo and PF-00547659 groups, respectively (p=0.156).
Endoscopic improvement was higher, but not significantly
different, in patients receiving PF-00547659 compared to pla-
cebo. Larger clinical trials evaluating efficacy of PF-
00547659 in CD and UC will be completed in 2015. The
safety of this agent regarding central nervous system infec-
tions appeared reassuring in the TOSCA trial, an open-label
study in which patients with active CD had lumbar punctures
before and after anti-MAdCAM treatment. No changes in ce-
rebrospinal fluid cell populations were detected (D’Haens G
et al., abstract presentation ECCO 2014, OP007).
Anti-CCR 9 (Vercirnon)
The chemokine receptor CCR9 plays an important role in the
process of gut homing of leucocytes. CCX282-B, also called
Vercirnon or Traficet-EN (ChemoCentryx, Inc., CA, USA), is
a chemokine receptor CCR9 antagonist that is orally admin-
istered. This drug interferes with migration and activation of
inflammatory cells in the intestine [28•]. Recently, safety and
efficacy of this drug were evaluated in more than 400 CD
patients who received placebo or CCX282-B (250 or
500 mg once daily or 250 mg twice daily) for 12 weeks,
followed by 250 mg CCX282-B twice daily up to week 16
(open-label) [28•]. Week 16 clinical responders were random-
ized to receive CCX282-B (250mg twice daily) or placebo for
36 weeks. Response rates at week 8 were 49 % in the placebo
group, 52 % in the CCX282-B 250 mg once daily group (p=
0.667 versus placebo), 48 % in the CCX282-B 250 mg twice
daily group (p=0.833), and 60 % in patients receiving once-
daily CCX282-B 500 mg (p=0.111). Remission rates at week
52 were seen in 47 % of patients on CCX282-B versus 31 %
of patients on placebo (p=0.012); 46 % showed a sustained
clinical response compared to 42 % in the placebo arm (p=
0.629). Treatment with this small-molecule inhibitor was well
tolerated. The initial trial by ChemoCentryx was followed by
a l a rge phase 3 p rog r am in CD sponso r ed by
GlaxoSmithKline. Surprisingly, the initial results could not
be reproduced. The trial was negative without even a hint of
efficacy of CCX282-B. The program was immediately
discontinued (Feagan B et al., abstract presentation CCFA
2013).
Novel Small Molecules
Orally active small molecules interfere with intracellular sig-
naling. Compared to therapeutic antibodies, small molecules
have certain advantages, including lower production costs and
usually oral route of administration. Most advanced in their
development are the Janus kinase (JAK) inhibitors, one of
which is already approved and marketed for the treatment of
rheumatoid arthritis in the USA.
Tofacitinib
JAKs play a key role in regulating cellular proliferation, dif-
ferentiation, and immune cell functions. They can convert
extracellular signals (cytokines, growth factors, etc.) into ge-
nomic responses. JAK-dependent intracellular signaling path-
ways are involved in the pathophysiology of many chronic
inflammatory disorders, including rheumatoid arthritis and
IBD [29–31]. Hence, JAK inhibitors have become attractive
anti-inflammatory agents although they carry the risk of pro-
found systemic immunosuppression.
Tofacitinib inhibits JAK1 and JAK3 signaling resulting in
reduced synthesis of pro-inflammatory cytokines. A phase 2
trial in 194 patients with moderate to severe active UC
assessed safety and efficacy of tofacitinib at doses of 0.5, 3,
10, or 15 mg or placebo twice daily for 8 weeks [32••]. Clin-
ical response at week 8 (primary outcome) was seen in 32, 48,
61, and 78 % of patients receiving tofacitinib at a dose of
0.5 mg (p=0.39), 3 mg (p=0.55), 10 mg (p=0.10), and
15 mg (p<0.001), respectively, as compared with 42 % of
patients in the placebo group. Week 8 clinical remission was
observed in 13, 33, 48, and 41 % of patients receiving
tofacitinib at doses of 0.5 mg (p=0.76), 3 mg (p=0.01),
10 mg (p<0.001), and 15 mg (p<0.001), respectively, versus
10 % of patients in the placebo group. Endoscopic remission
at 8 weeks (defined as a Mayo endoscopy subscore of 0) was
seen in 2 % of patients receiving placebo, compared to 10 %
receiving 0.5 mg tofacitinib (p=0.14), 18 % receiving 0.5 mg
tofacitinib (p=0.01), 30 % receiving 10 mg tofacitinib
(p<0.001), and 27 % receiving 15 mg tofacitinib (p<0.001).
Two phase 3 registration trials are ongoing.
Tofacitinib was also evaluated in patients with moderate to
severe active CD [33•]. Patients were randomized to receive
tofacitinib twice daily for 4 weeks at doses of 1 mg, 5 mg,
15 mg, or placebo. Clinical response rates at week 4 (primary
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endpoint) were 36 % (p=0.467), 58 % (p=0.466), and 46 %
(p≥0.999) of patients given 1, 5, or 15 mg tofacitinib twice
daily versus 47 % of patients given placebo. Clinical remis-
sion at week 4 (secondary endpoint) was seen in 31 % (p=
0.417), 24 % (p=0.776), and 14 % (p=0.540) of patients
given 1, 5, and 15 mg tofacitinib, versus 21 % of patients
given placebo. Strictly, this trial was negative, but the placebo
response and remission rates were unexpectedly high. A re-
duction in fecal calprotectin and C-reactive protein levels
among patients receiving 15 mg tofacitinib twice daily indi-
cated its biologic activity. A repeat phase 2 trial with stricter
inclusion criteria defining active disease is ongoing. Mean-
while, the maximum dose of 15 mg twice daily has been
abandoned given the lack of superiority over 10 mg twice
daily.
Tofacitinib seems to have an acceptable safety profile in
UC and CD patients, although herpes zoster infections have
been observed quite frequently. In rheumatoid arthritis, sever-
al cases of lymphoma were reported, but the overall risks of
infections and mortality with tofacitinib seem to be similar to
those observed with biologicals [34]. In addition, a dose-
dependent increase in low-density and high-density lipopro-
tein cholesterol concentrations occurred. It is unclear what the
long-term effects of this phenomenon could be. The most
attractive property of the JAK inhibitors is that they can be
used as monotherapy and that they are orally available. Other
JAK inhibitors are currently under clinical investigation in
phase 2 for both CD and UC.
Laquinimod
Laquinimod is an oral immunomodulator that induces
anti-inflammatory effects by modulating immune cells
resulting in reduced synthesis of several cytokines. The
agent was effective in suppressing disease activity in
multiple sclerosis and seems to have a favorable safety
profile [35]. Laquinimod is also in development for the
treatment of CD. Recently, a phase 2a trial was pub-
lished in which patients with active CD received differ-
ent doses of laquinimod (0.5, 1, 1.5, or 2 mg/day) for
8 weeks [36•]. Clinical remission at week 8 was seen in
48.3, 26.7, 13.8, and 17.2 % of patients receiving 0.5,
1, 1.5, and 2 mg laquinimod versus 15.9 % in the
placebo group. Interestingly, clinical benefit was most
pronounced at week 8 with the lowest dose whereas
the 1.5- and 2-mg doses appeared ineffective. Overall,
induction treatment with laquinimod was reasonably
well tolerated with headache, abdominal pain, nausea,
vomiting, and musculoskeletal pain as the most common
adverse effects. All laquinimod doses were found to
reduce fecal calprotectin levels in these patients. Further
studies with this small molecule are warranted.
Antinucleotide Therapy
SMAD7 Antisense (Mongersen, GED-301)
The safety and efficacy of Mongersen, an orally administered
SMAD7 antisense oligonucleotide (Celgene, Switzerland),
were recently studied in a placebo-controlled phase 2 study
in patients with active CD (Monteleone G et al. abstract pre-
sentation UEGW 2014, OP203). SMAD7 is an endogenous
inhibitor of the immunosuppressive cytokine transforming
growth factor-β1. Patients were randomized to receive induc-
tion treatment with different doses of Mongersen or placebo
for 2 weeks. Clinical remission (primary outcome parameter)
was seen in 55.0, 65.1, and 9.5 % of patients receiving
Mongersen 40 mg/day, 160 mg/day, or placebo (p<0.0001,
for both comparisons) at 15 days andmaintained for ≥2weeks.
Adverse events were similar across the treatment groups. This
promising molecule is now being investigated in larger trials.
Conclusion
Anti-TNF agents have been on the market for more than
15 years and have found an established place in the therapeu-
tic armamentarium, primarily moderate to severe UC and CD.
In CD, evidence suggests that earlier introduction leads to
superior outcomes and higher rates of mucosal healing. The
latest addition to the anti-TNF class of drugs is golimumab, a
subcutaneous human anti-TNF agent that was recently ap-
proved by the FDA and EMA for the treatment of moderately
to severely active UC. Given the fact that only one third of CD
and UC patients show a durable response to all available anti-
TNF agents, there remains an unmet need for novel treatment
options. Oral TNF blockers could offer an attractive option.
Recent trials showed that the gut-selective integrin inhibi-
tor vedolizumab (an antibody that blocks α4β7-MAdCAM-1
interactions) is efficacious for UC and CD, but the results
seem to be better in UC. Other adhesion molecule blockers
(including etrolizumab and PF-00547659) also showed prom-
ising clinical effects in UC but need further trials. The anti-
integrin antibodies appear to be well tolerated, although long-
term efficacy and toxicity data need to be collected.
Various small molecules that interfere with inflammatory
pathways are currently under development or are being eval-
uated in clinical trials. Tofacitinib has shown promising clin-
ical effects in UC and is in phase 3. Other JAK inhibitors are in
the therapeutic pipeline and might find their way to the market
as well. Laquinimod may hold promise for CD. Finally,
Mongersen (GED-0301), a SMAD7 antisense nucleotide with
magnificent phase 2 results, will soon enter phase 3. The
question is how these novel agents will be positioned in future
IBD treatment algorithms. Vedolizumab has the potential to
become a first-line biologic for the treatment of UC. The JAK
21 Page 6 of 8 Curr Gastroenterol Rep (2015) 17: 21
inhibitor tofacinitib may also appear on the market for UC in
the foreseeable future, depending on the outcome of the on-
going phase 3 trials. Looking at the wide range ofmolecules in
the development for IBD, the therapeutic options in these
conditions will improve to an important extent and the posi-
tioning of the conventional agents is likely to change
significantly.
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